Uster

Researchers are evaluating the effects of lysergic acid diethylamide (LSD) on psychosocial distress in 60 patients with advanced or end-stage fatal diseases who have a life expectancy between 12 weeks and 2 years. The study focuses on symptoms such as depressed mood, anxiety, pain, demoralization, fear of death, existential distress, and overall quality of life. This phase II trial uses an active placebo-controlled, double-blind, parallel design to assess how LSD may impact these challenging symptoms in palliative care. Participants will be randomly assigned in a 2:1 ratio to receive either two moderate to high oral doses of LSD (100 µg followed by 100 µg or 200 µg) or two low doses of LSD (25 µg followed by 25 µg) as an active placebo. The dosing schedule involves two interventions, and the study monitors the effects of these different LSD dose levels to understand their impact on the patients' condition. During the study, researchers will assess changes in state anxiety using a questionnaire called the State Anxiety Inventory (STAI-S) at baseline and two weeks after the second intervention. Participants must follow safety guidelines, including not driving or operating machinery within 24 hours after LSD administration. The study involves careful monitoring and evaluations to measure anxiety changes and other psychosocial outcomes, with attention to safety and adherence to study procedures throughout the trial.

Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that arise from the neuroendocrine system in the gastrointestinal tract and pancreas. This registry study aims to better understand these tumors by collecting detailed clinical information from patients diagnosed with GEP-NETs in Switzerland. Since limited knowledge exists about the biology and treatment of these tumors, the study focuses on gathering data to improve understanding and management strategies. Patients with a confirmed diagnosis of neuroendocrine tumors from any location who agree to participate will have their information entered prospectively into a secure, anonymized database. Data collection involves visits from study nurses to healthcare centers, where patient files are reviewed and information is recorded. There are no specific treatments assigned by this registry; instead, it tracks various treatment approaches used in Switzerland. Participants contribute data that includes tumor types, treatments received, and outcomes such as mortality and hospitalization rates. The study reviews and evaluates this information regularly to identify patterns and assess patient outcomes over time. The main outcome measured is tumor-related mortality every five years, helping to monitor long-term effects. This registry allows for improved knowledge sharing across hospitals and practitioners in Switzerland to enhance care for patients with neuroendocrine tumors.

Researchers are studying patients with moderate-to-severe atopic dermatitis (AD), a common chronic inflammatory skin disease that significantly affects quality of life and has a high socioeconomic impact. This Swiss national, prospective, non-interventional, multicenter registry aims to fill the gap in detailed data about AD management. The study focuses on documenting the medical care of these patients to evaluate treatment appropriateness and to collect information on psychosocial effects, epidemiology, risk factors, and comorbidities. The study includes children aged 12 years and older, adolescents, and adults with moderate-to-severe AD. No study-related interventions or treatments are given. Participants are followed prospectively for at least 24 months, with no maximum follow-up duration intended. During this time, standardized visits collect detailed patient characteristics, clinical data, patient-reported outcomes, reasons for treatment decisions, and satisfaction with therapies. The study observes the use of approved systemic drugs and other treatments as they occur in routine medical care. Participants will undergo regular evaluations to record disease status, treatment use, and quality of life impacts. Researchers will monitor the type of systemic therapy used over 24 months as the main outcome. The study seeks to establish a clinical research network and support future projects by providing comprehensive, real-world data. Patient consent is required, and those enrolled contribute data through follow-up visits without additional treatments imposed by the study.